The Food and Drug Administration yesterday approved its first “biosimilar” drug — a lower-cost version of an expensive, complex medication — which could boost market competition and lead to billions of dollars in savings for insurers and patients. Aaron Kesselheim, associate professor of medicine at Brigham and Women’s Hospital, is quoted.
